Back to Hematology
Hematologyv2017Evidence-Based

MALT Lymphoma Prognostic Index (MALT-IPI)

Identifies MALT lymphoma patients at risk for poor outcomes using three clinical parameters: age ≥70 years, Ann Arbor stage III/IV, and elevated lactate dehydrogenase (LDH). Stratifies patients into low, intermediate, and high risk groups predictive for event-free survival and overall survival.

Clinical Input Parameters

years
Range: 18 — 120 years
Clinical Assessment
Awaiting Parameters
malt ipi score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The MALT Lymphoma Prognostic Index (MALT-IPI) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

MALT-IPI Score = Age points + LDH points + Ann Arbor Stage points. Age ≥70 years (1 point), elevated LDH (1 point), Ann Arbor stage III/IV (1 point). Total score 0 = Low risk, 1 = Intermediate risk, ≥2 = High risk.

Clinical Pearls & Practice Notes

  • Developed using 401 patients from the IELSG-19 randomized trial and validated in independent cohort (N=633)
  • Applicable to both gastric and non-gastric MALT lymphoma patients
  • Prognostic utility retained across different treatment arms (chlorambucil, rituximab, rituximab plus chlorambucil)
  • Simple, accessible tool that significantly discriminates between patients with different progression-free, overall, and cause-specific survival
  • May help define appropriate treatment approaches for individual patients
  • Age ≥70 years, Ann Arbor stage III/IV, and elevated LDH were independently associated with worse event-free survival in multivariate analysis

Evidence & Literature Citations

  1. Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, et al. A MALT lymphoma prognostic index. Blood. 2017 Sep 21;130(12):1409-1417. doi: 10.1182/blood-2017-03-771915.
  2. Hong J, Lee Y, Park J, Kim SJ, Lim ST, Kim JS, et al. Validation of the MALT-lymphoma international prognostic index (MALT-IPI) and extension of the prognostic model with the addition of β2-microglobulin. Ann Hematol. 2019 Nov;98(11):2499-2507. doi: 10.1007/s00277-019-03808-x.
  3. Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, et al. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Agent Alone. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994.

Score Interpretation Ranges

Low Risk0 – 0 pts

Low risk of poor outcomes

Intermediate Risk1 – 1 pts

Intermediate risk of poor outcomes

High Risk2 – 3 pts

High risk of poor outcomes

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.